Axsome Therapeutics EPS - Earnings per Share 2014-2025 | AXSM

Axsome Therapeutics earnings per share (EPS) for the twelve months ending March 31, 2025 was $-5.77, a 10.54% decline year-over-year.

  • Axsome Therapeutics EPS for the quarter ending March 31, 2025 was $-1.22, a 15.28% decline year-over-year.
  • Axsome Therapeutics 2024 annual EPS was $-5.99, a 13.66% increase from 2023.
  • Axsome Therapeutics 2023 annual EPS was $-5.27, a 14.57% increase from 2022.
  • Axsome Therapeutics 2022 annual EPS was $-4.6, a 32.56% increase from 2021.

Earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.

Axsome Therapeutics EPS - Earnings per Share 2014-2025 | AXSM

  • Axsome Therapeutics EPS for the quarter ending March 31, 2025 was $-1.22, a 15.28% decline year-over-year.
  • Axsome Therapeutics 2024 annual EPS was $-5.99, a 13.66% increase from 2023.
  • Axsome Therapeutics 2023 annual EPS was $-5.27, a 14.57% increase from 2022.
  • Axsome Therapeutics 2022 annual EPS was $-4.6, a 32.56% increase from 2021.

Earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$209.6B
Amgen (AMGN)$149.1B
Gilead Sciences (GILD)$130.2B
Vertex Pharmaceuticals (VRTX)$125.6B
Bristol Myers Squibb (BMY)$100.2B
CSL (CSLLY)$74.3B
GSK (GSK)$74.1B
Regeneron Pharmaceuticals (REGN)$61.6B
Argenex SE (ARGX)$36.2B
Alnylam Pharmaceuticals (ALNY)$30.5B
BioNTech SE (BNTX)$23.7B
BeiGene (ONC)$22.8B
Biogen (BIIB)$17.4B
Genmab (GMAB)$13.3B
Genmab (GNMSF)$13.3B
Insmed (INSM)$13.2B
BioMarin Pharmaceutical (BMRN)$11.3B
Illumina (ILMN)$11.3B
Incyte (INCY)$11.3B
Ascendis Pharma (ASND)$10.1B
Exelixis (EXEL)$10B
Swedish Orphan Biovitrum (BIOVF)$9.6B
Moderna (MRNA)$9.6B
QIAGEN (QGEN)$9B
Exact Sciences (EXAS)$7.7B
Bio-Techne Corp (TECH)$7.6B
Repligen (RGEN)$7.3B
Halozyme Therapeutics (HALO)$7.3B
Roivant Sciences (ROIV)$7.2B
Revolution Medicines (RVMD)$6.8B